“Metabolites of nitric oxide (NO) pathway are altered and indicative of reduced NO and arginine bioavailability in patients with cardiometabolic diseases complicated with chronic wounds of lower extremities – targeted metabolomics approach (LC-MS/MS)” by Krzystek-Korpacka et al.

|  |  |
| --- | --- |
|  |  |
|  |  |
|  |  |

**Supplementary Figure 2:** The association of gangrene type with intermediates in arginine/NO pathway: **(a)** arginine; **(b)** citrulline; **(c)** ADMA; **(d)** SDMA; **(e)** arginine-to-ADMA ratio (Arg/ADMA); **(f)** arginine-to-SDMA ratio (Arg/SDMA). Data presented as means with 95% confidence intervals and analyzed using t-test for independent samples.